CTI BioPharma

company

About

CTI BioPharma is a biopharmaceutical company developing oncology products for the treatment of cancer.

  • 251 - 500

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$5M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 1991
Number Of Employee
251 - 500
Operating Status
Active

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$5M
CTI BioPharma has raised a total of $5M in funding over 2 rounds. Their latest funding was raised on Dec 18, 2013 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 18, 2013 Post-IPO Debt $5M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
CTI BioPharma is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Post-IPO Debt